BRPI0719166A2 - Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos - Google Patents

Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos

Info

Publication number
BRPI0719166A2
BRPI0719166A2 BRPI0719166-9A2A BRPI0719166A BRPI0719166A2 BR PI0719166 A2 BRPI0719166 A2 BR PI0719166A2 BR PI0719166 A BRPI0719166 A BR PI0719166A BR PI0719166 A2 BRPI0719166 A2 BR PI0719166A2
Authority
BR
Brazil
Prior art keywords
therapeutic agents
tricyclic spiro
oxindol derivatives
oxindol
derivatives
Prior art date
Application number
BRPI0719166-9A2A
Other languages
English (en)
Inventor
Mikhail Chafeev
Sultan Chowdhury
Jianmin Fu
Rajender Kamboj
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of BRPI0719166A2 publication Critical patent/BRPI0719166A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0719166-9A2A 2006-10-12 2007-10-12 Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos BRPI0719166A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85119006P 2006-10-12 2006-10-12
PCT/US2007/081240 WO2008046046A1 (en) 2006-10-12 2007-10-12 Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0719166A2 true BRPI0719166A2 (pt) 2014-06-03

Family

ID=39046816

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719166-9A2A BRPI0719166A2 (pt) 2006-10-12 2007-10-12 Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos

Country Status (9)

Country Link
US (1) US20110237567A9 (pt)
EP (1) EP2076518A1 (pt)
JP (1) JP2010522690A (pt)
CN (1) CN101522685A (pt)
AU (1) AU2007307635A1 (pt)
BR (1) BRPI0719166A2 (pt)
CA (1) CA2666136A1 (pt)
MX (1) MX2009003874A (pt)
WO (1) WO2008046046A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2407469A1 (en) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
CN102584860B (zh) * 2011-01-17 2014-12-10 苏州大学 含吲哚结构的螺杂环化合物及其制备方法
EP2860180A1 (en) * 2011-03-03 2015-04-15 Cadila Healthcare Limited Novel gentisate salts of DPP-IV inhibitor
NO3175985T3 (pt) * 2011-07-01 2018-04-28
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
MX360323B (es) 2012-04-25 2018-10-29 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de ttx-s.
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
US11149039B2 (en) 2017-10-10 2021-10-19 Biogen Inc. Process for preparing spiro derivatives

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) * 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
US3723459A (en) * 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CH577461A5 (pt) * 1975-08-13 1976-07-15 Robins Co Inc A H
US4670566A (en) * 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) * 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) * 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) * 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US5182289A (en) * 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5116854A (en) * 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5278162A (en) * 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) * 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) * 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
AT400950B (de) * 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
JPH09511514A (ja) * 1994-04-07 1997-11-18 セ・エ・エム・ア・エフ 新規メラトニン作用性アゴニストのスピロ［インドールピロリジン］誘導体とその製造方法および医薬品としての用途
US5618819A (en) * 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
FR2740136B1 (fr) * 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998031378A1 (de) * 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
JP3833532B2 (ja) * 1999-07-21 2006-10-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性疾患の治療において有用な小分子
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU2002318206A1 (en) * 2001-08-14 2003-03-03 Jolie Anne Bastian 3-substituted oxindole beta-3 agonists
ATE297925T1 (de) * 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
SE0104341D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New use
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
MXPA05012320A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Tratamientos de trastornos bipolares y sintomas asociados.
EP1633360A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Treatment of psychotic and depressive disorders
MXPA05012325A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
US20070299102A1 (en) * 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
CA2603818A1 (en) * 2005-04-29 2006-11-09 Wyeth Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
AR057023A1 (es) * 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents

Also Published As

Publication number Publication date
WO2008046046A1 (en) 2008-04-17
AU2007307635A1 (en) 2008-04-17
CA2666136A1 (en) 2008-04-17
MX2009003874A (es) 2009-04-22
US20100160291A1 (en) 2010-06-24
JP2010522690A (ja) 2010-07-08
CN101522685A (zh) 2009-09-02
EP2076518A1 (en) 2009-07-08
US20110237567A9 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
BRPI0719166A2 (pt) Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
BRPI0908225A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0920448A2 (pt) compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0810858A2 (pt) Derivados de 2-heteroaril-pirrolo[3,4-c] pirrol e seus usos como inibidores de scd
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI0817881A2 (pt) Compostos orgânicos e seus usos
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0810679A2 (pt) Derivados de 4-aza indol e seu uso como fungicidas
BRPI0710878A2 (pt) Compostos orgânicos e seus usos
BR112012000370A2 (pt) derivados de 1,2,4-tiazolidin-3-ona e seus usos no tratamento de câncer
BRPI0809103A2 (pt) composições de magnésio e seus usos
BRPI0719210A2 (pt) Uso de compostos espiro-oxindol como agentes terapêuticos
PT3001903T (pt) 1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BRPI0910746A2 (pt) reticuladores e seus usos
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BR112012000660A2 (pt) compostos heterociclos e seus usos
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
BRPI0813244A2 (pt) Compostos e seus usos 708
PT2473527T (pt) Formulações estáveis de polipéptidos e seus usos
ZA201002959B (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
BRPI1012697A2 (pt) derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
BRPI0913885A2 (pt) Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI0819519A2 (pt) Análogos de triarilmetano e seus usos no tratamento de cânceres.

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 4A, 5A, 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.